• Naruto
• One Piece
• Pastel
• Bleach
• Air Gear
• Mx0
• To Love-RU
• Hatsukoi Limited
• Code Breaker
• Double Arts
• Berserk
• Katekyo Hitman Reborn!

• A-D and Special Chars
• E-J
• K-N
• O-R
• S-V
• W-Z

• All manga
• Action manga
• Adventure manga
• Comedy manga
• Cooking manga
• Drama manga
• Ecchi manga
• Fantasy manga
• Gender bender manga
• Historical manga
• Horror manga
• Josei manga
• Martial arts manga
• Mature manga
• Mecha manga
• Music manga
• Mystery manga
• One shot manga
• Psychological manga
• Romance manga
• School life manga
• Seinen manga
• Shoujo manga
• Shounen manga
• Slice of life manga
• Sports manga
• Supernatural manga

• Mangacopycat
• Free .co.nr

Yahoo! Finance: Biotechnology Industry News

Theravance antibiotic wins FDA panel OK (at bizjournals.com)

FDA Accepts Vanda Pharmaceuticals Iloperidone Resubmission and Sets New Action Date (PR Newswire)
Vanda Pharmaceuticals Inc. , a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders, reported today that the FDA has accepted Vanda's resubmission of the iloperidone New Drug Application .

Duska Therapeutics Provides Program Update and Reports Third Quarter 2008 Financial Results (PR Newswire)
Duska Therapeutics, Inc. will host a teleconference call today at 2:30 p.m. EST to review its drug development programs and financial results for the third quarter of 2008. Duska's chief executive officer, James S.

Targacept Scientists Make Multiple Presentations at Society for Neuroscience Supporting the Potential of NNR Therapeutics to Treat CNS Diseases and Disorders (Business Wire)
WINSTON-SALEM, N.C.----Targacept, Inc. , a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics , today announced that its scientists recently made several presentations at the 38th annual meeting of the Society for Neuroscience .

Duska Therapeutics Applies for Phase 3 Special Protocol Assessment (PR Newswire)
Duska Therapeutics, Inc., , announced today that it has submitted its pivotal Phase 3 ATPace clinical trial protocol for review under a Special Protocol Assessment procedure with the U.S.

Invitrogen and Applied Biosystems Announce Preliminary Results of Election Regarding Merger Consideration (Business Wire)
CARLSBAD, Calif. & NORWALK, Conn.----Invitrogen Corporation and Applied Biosystems Inc. today announced the preliminary results of elections made by Applied Biosystems stockholders regarding their preferences as to the form of merger consideration they will receive in the pending acquisition of Applied Biosystems by Invitrogen.

ImClone gets drug candidate manufacturing approval (AP)
ImClone Systems Inc. said Thursday it received approval to make three cancer drug candidates at a facility in New Jersey, as it prepares to ramp up late-stage trials of the products.

Clinical Data Participates in MAb IMPACT Meeting to Improve Clinical Efficacy of Monoclonal Antibodies for Cancer Treatment (Business Wire)
NEWTON, Mass.----PGxHealth®, a division of Clinical Data, Inc. , today announced its participation in the international mAb IMPACT meeting which is focused on IMProving ACTivation of the FCGR3A pathway for optimizing the treatment of cancer.

Nabi Biopharmaceuticals Q3 2008 Earnings Call Transcript (at Seeking Alpha)

Cougar Biotechnology Announces Initiation of Phase I/II Trial of CB7630 (Abiraterone Acetate) in Advanced Breast Cancer Patients (Business Wire)
LOS ANGELES----Cougar Biotechnology, Inc. today announced that the first patient was enrolled in a Phase I/II clinical trial of the Company’s drug candidate CB7630 , an orally active inhibitor of the steroidal enzyme 17alpha-hydroxylase/C17,20 lyase, for the treatment of advanced breast cancer.

Cavit Sciences, Inc. Announces Update to Shareholders (Marketwire)

Affymax Announces Another Favorable Data Monitoring Committee Review of Phase 3 Hematide Program (Business Wire)

Alnylam Presents Pre-clinical Data from TTR Amyloidosis Development Program (Business Wire)
CAMBRIDGE, Mass.----Alnylam Pharmaceuticals, Inc. , a leading RNAi therapeutics company, announced today that it presented new pre-clinical data from its TTR amyloidosis development program at Cambridge Healthtech Institute’s Drug Formulation conference held in Philadelphia, November 19-20, 2008.

Bioheart Announces CE Marking for TGI 1200(tm) Adult Stem Cell Isolation System (GlobeNewswire)

Idera Pharmaceuticals and Merck & Co., Inc. Extend Research Collaboration for Agonists of Toll-like Receptors (Business Wire)
CAMBRIDGE, Mass.----Idera Pharmaceuticals, Inc. today announced that Merck & Co., Inc. has extended its research collaboration with Idera for an additional year. The Company and Merck entered into an exclusive license and research collaboration agreement to research, develop and commercialize vaccine products containing the Company’s investigational agonist compounds targeting Toll-like Receptors 7, 8, and 9 in the fields of oncology, infectious diseases and Alzheimer’s disease in December 2006.